The short version of adipose tissue fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2026-05-26 and is reviewed periodically as new material appears.
The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.
In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.
Proposed mechanism focuses on lipolysis, the breakdown of stored triglycerides into free fatty acids and glycerol. AOD-9604 is thought to act on adipose tissue without stimulating appetite or affecting blood sugar in the same way as growth hormone. Laboratory studies report increased fat oxidation in some models. The precise receptor interactions and signaling pathways remain incompletely characterized. Researchers have proposed that the peptide may influence fat mobilization through pathways distinct from the full hormone.
Research has examined whether the peptide affects fat mass independently of growth hormone's other actions. Early animal studies suggested reductions in body fat, but species differences and small sample sizes limit interpretation. Human studies have generally been short and have not consistently shown large effects. Some trials measured body composition, lipid profiles, and safety parameters, but the overall picture is one of suggestive yet inconclusive metabolic activity. Findings vary across study populations and protocols.
A central uncertainty is whether observed metabolic changes translate into meaningful clinical benefits. Study designs vary in dose, duration, and participant characteristics, making comparisons difficult. Independent replication is limited, and the field lacks consensus on optimal endpoints or treatment duration. Ongoing or future studies may clarify mechanism and effect size, but current evidence does not establish a clear therapeutic role. Researchers often call for larger, longer, and better-controlled trials, while questions remain about which patient groups might respond.
| Property | Value | Notes |
|---|---|---|
| Common synonym | hGH fragment 176-191 | Refers to the C-terminal segment |
| Appearance | White to off-white powder | Typically supplied lyophilized |
| Solubility | Soluble in water and aqueous buffers | Confirm with technical data |
| Typical storage temperature | -20 °C for dry powder | Protect from moisture and light |
| Common analytical method | RP-HPLC with UV detection | Often paired with mass spectrometry |
Laboratory studies have reported that AOD9604 can increase lipolysis and reduce lipid accumulation in fat cells. The precise molecular target remains uncertain, and the compound does not appear to activate the growth hormone receptor in the same way as full-length hGH. Proposed mechanisms include effects on beta-adrenergic signaling and enzymes involved in fatty acid synthesis, but these pathways are not firmly established. Because most evidence comes from cell and animal models, whether the same effects occur in humans is an open question.
Clinical development of AOD9604 included trials in people with obesity, but the results did not lead to approval as a prescription medicine in major markets. Interest later shifted to research settings and to unapproved products marketed for body composition. Regulatory agencies have questioned whether the peptide qualifies as a dietary ingredient, and some have issued warnings about its presence in supplements. Long-term human safety data are limited, and questions about efficacy, dosing, and target populations remain unresolved.
AOD9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to a short sequence near the end of the 191-amino-acid hormone, often described as residues 176–191 or a related fragment. Researchers designed it to separate metabolic effects from the growth-promoting actions of full-length growth hormone. Early work in the 1990s explored it as a candidate for weight and lipid disorders. It is not a naturally circulating hormone fragment produced in large amounts.
Quality varies among research-grade suppliers, so certificates of analysis and independent testing are important for verification. A typical certificate reports purity by HPLC, identity by mass spectrometry, appearance, and sometimes residual solvents or water content. AOD9604 is often sold as a research chemical not intended for human consumption, and labels can be inaccurate. Common misconceptions include treating the peptide as a form of growth hormone, assuming supplement status, or expecting approved-drug quality from unregulated products.
AOD9604 is commonly supplied as a white to off-white lyophilized powder. The powder is typically stored at -20 °C or below, protected from light and moisture, because peptides can degrade through oxidation, hydrolysis, or aggregation. If it is reconstituted for laboratory use, an appropriate aqueous buffer or solvent is chosen, and the solution is kept cold and handled to avoid repeated freeze-thaw cycles. These practices support stability but do not imply suitability for human use.
Identity and purity are usually assessed with reversed-phase high-performance liquid chromatography and mass spectrometry. Reversed-phase HPLC separates the peptide from related impurities and can estimate purity by ultraviolet absorbance, while mass spectrometry confirms the molecular mass and detects modifications. Peptide mapping, amino acid analysis, and disulfide mapping may be used when the sequence or disulfide arrangement must be verified. Because AOD9604 contains cysteine residues, oxidation and disulfide isomers are possible quality concerns in synthetic batches.
Joseph Nightingale (1813), "Bristol", Beauties of England and Wales, vol. 13, London: J. Harris, Somersetshire James Dugdale (1819), "Somersetshire: Bristol", New British Traveller, vol. 4, London: J. Robins and Co. John Evans (1828), The New Guide, or, Picture of Bristol (4th ed.), Bristol, OCLC 45137262, OL 13521980M "Bristol", Great Western Railway Guide, London: James Wyld, 1839, OCLC 12922212 "Bristol", Black's Picturesque Tourist and Road-book of England and Wales (3rd ed.), Edinburgh: Adam and Charles Black, 1853 John Parker Anderson (1881), "Gloucestershire: Bristol", Book of British Topography: a Classified Catalogue of the Topographical Works in the Library of the British Museum Relating to Great Britain and Ireland, London: W. Satchell William Clark Russell (1883). "Bristol". North-East Ports and Bristol Channel. Newcastle-upon-Tyne: A. Reid. hdl:2027/uc1.$b667579. How to See Bristol. Bristol: Arrowsmith. 1893. "Bristol", Great Britain (4th ed.), Leipsic: Karl Baedeker, 1897, OCLC 6430424 Charles Gross (1897). "Bristol". Bibliography of British Municipal History. New York: Longmans, Green, and Co. Francis Adams Hyett; William Bazeley (1897). Bibliographer's Manual of Gloucestershire Literature. Vol. 3: City of Bristol. Dallaway, James (1834). Antiquities of Bristow in the Middle Centuries: including the topography by William Wyrcestre, and the life of William Canynges. Bristol: Mirror Office. Published in the 20th century
=== Natural occurrence === Nanoparticles are naturally produced by many cosmological, geological, meteorological, and biological processes. A significant fraction (by number, if not by mass) of interplanetary dust, that is still falling on the Earth at the rate of thousands of tons per year, is in the nanoparticle range; and the same is true of atmospheric dust particles. Many viruses have diameters in the nanoparticle range.
Liver transplantation is the only option for those with irreversible liver failure. Most transplants are done for chronic liver diseases leading to cirrhosis, such as chronic hepatitis C, alcoholism, and autoimmune hepatitis. Less commonly, liver transplantation is done for fulminant hepatic failure, in which liver failure occurs rapidly over a period of days or weeks. Liver allografts for transplant usually come from donors who have died from fatal brain injury. Living donor liver transplantation is a technique in which a portion of a living person's liver is removed (hepatectomy) and used to replace the entire liver of the recipient. This was first performed in 1989 for pediatric liver transplantation. Only 20 percent of an adult's liver (Couinaud segments 2 and 3) is needed to serve as a liver allograft for an infant or small child. More recently, adult-to-adult liver transplantation has been done using the donor's right hepatic lobe, which amounts to 60 percent of the liver. Due to the ability of the liver to regenerate, both the donor and recipient end up with normal liver function if all goes well. This procedure is more controversial, as it entails performing a much larger operation on the donor, and indeed there were at least two donor deaths out of the first several hundred cases. A 2006 publication addressed the problem of donor mortality and found at least fourteen cases. The risk of postoperative complications (and death) is far greater in right-sided operations than that in left-sided operations.
Sources: en.wikipedia.org
=== EC 2.4: glycosyl, hexosyl, and pentosyl transferases === EC 2.4 includes enzymes that transfer glycosyl groups, as well as those that transfer hexose and pentose. Glycosyltransferase is a subcategory of EC 2.4 transferases that is involved in biosynthesis of disaccharides and polysaccharides through transfer of monosaccharides to other molecules. An example of a prominent glycosyltransferase is lactose synthase which is a dimer possessing two protein subunits. Its primary action is to produce lactose from glucose and UDP-galactose. This occurs via the following pathway: UDP-β-D-galactose + D-glucose
Genetics (from Ancient Greek γενετικός genetikos, "genite" and that from γένεσις genesis, “origin”), a discipline of biology, is the science of heredity and variation in living organisms. Articles (arranged alphabetically) related to genetics include:
==== Irradiation ==== Food irradiation is another notable biological engineering process to achieve food safety. Research into the potential utilization of ionizing irradiation for food preservation started in the 1940s as an extension of studies on the effect of radiation on living cells. The FDA approved usage of ionizing radiation on food products in 1990. This radiation removes electrons from atoms, and these electrons go on to damage the DNA of microorganisms living in the food, killing the microorganisms. Irradiation can be used to pasteurize food products, such as seafood, poultry, and red meat, thus making these food products safer for consumers. Some irradiation is also used to delay fruit ripening processes, which can kill microorganisms that accelerate the ripening and spoilage of produce. Low dosages of radiation can also be used to kill insects living in harvested crops, as the radiation will stunt the insects' development at various stages and damage their ability to reproduce.
The computer failed on the 48th revolution when McDivitt tried to update it for reentry. It would not turn off and eventually stopped working altogether. This was unfortunate for IBM, which had just put an advertisement suggesting that its computers were so reliable that even NASA used them. The computer failure meant that the capsule would not be able to perform a closed-loop lifting reentry as planned. IBM were unable to duplicate the failure on the ground but they installed a manual override switch on subsequent Gemini missions. It was the only Gemini mission to experience a computer failure. Reentry came on the 62nd revolution. An open-loop rolling reentry (as used in Mercury) had to be used because of the computer failure. The astronauts began rolling the spacecraft at 120 kilometers (75 mi; 65 nmi) altitude to increase its stability. They started slowing the roll rate at 27,000 meters (89,000 ft) and stopped it by 12,000 meters (39,000 ft). The drogue parachute deployed shortly after this, and the main deployed at 3,200 meters (10,600 ft). A malfunctioning thruster caused the roll to be much faster than planned, and the landing was rough. Despite the rough landing, neither of the crew encountered any problems, contrary to NASA doctors' concerns about their landing upright – as opposed to on their backs, as in Mercury – after four days in space. Even though they landed 80 km (50 mi; 43 nmi) short of the intended landing target, some ships had already started steaming to the touchdown point, and a helicopter was able to see them land.
Sources: en.wikipedia.org
== Research == Sarkar discovered copper-histidine in human blood. He invented the treatment of Menkes disease by copper-histidine. He discovered the amino terminal Cu (II)- and Ni (II)- binding (ATCUN) motif of proteins. This motif has been used to cleave DNA, applied as a paramagnetic probe, and used to kill Ehrlich cells. His laboratory identified and characterized the six copper-binding sites of copper-ATPase that is defective in Wilson's disease. He pioneered the development of metalloproteomics, a subdiscipline of proteomics that attempts to identify and characterize all metal-associated proteins in a well-defined system. He also contributed to global health research in Bangladesh, India, Nepal, and Myanmar, where tens of thousands of people are exposed to naturally occurring arsenic and other toxic metals in drinking water from underground wells. Sarkar is considered a pioneer in establishing inorganic biochemistry through his research in the early 1960s. He organized the first international meeting of Biological Inorganic Chemistry in the boardroom of the Hospital for Sick Children in 1972. This initiative was followed by the 56th Nobel Symposium in Inorganic Biochemistry held in Sweden under the auspices of the Nobel Foundation in 1982, where Sarkar was an invited speaker. He has published extensively in scientific journals, organized many series of international symposia on metals and genetics, and edited several books on metals in biology, genetics, and environment.
Polyneuropathy (from Greek poly- 'many', neuro- 'nerve' and -pathy 'sickness') is damage or disease affecting peripheral nerves (peripheral neuropathy) in roughly the same areas on both sides of the body, featuring weakness, numbness, and burning pain. It usually begins in the hands and feet and may progress to the arms and legs and sometimes to other parts of the body where it may affect the autonomic nervous system. It may be acute or chronic. A number of different disorders may cause polyneuropathy, including diabetes and some types of Guillain–Barré syndrome.
The term "percent homology" is often used to mean "sequence similarity", that is the percentage of identical residues (percent identity), or the percentage of residues conserved with similar physicochemical properties (percent similarity), e.g. leucine and isoleucine, is usually used to "quantify the homology." Based on the definition of homology specified above this terminology is incorrect since sequence similarity is the observation, homology is the conclusion. The term "percent homology" is a misnomer; sequences are either homologous or not. As with morphological and anatomical structures, sequence similarity might occur because of convergent evolution, or, as with shorter sequences, by chance, meaning that they are not homologous. Homologous sequence regions are also called conserved. This is not to be confused with conservation in amino acid sequences, where the amino acid at a specific position has been substituted with a different one that has functionally equivalent physicochemical properties. Partial homology can occur where a segment of the compared sequences has a shared origin, while the rest does not. Such partial homology may result from a gene fusion event.
== Bibliography == Harrison, Alex. G. (1992). Chemical ionization mass spectrometry (2. ed.). Boca Raton, Fla. [u.a.]: CRC Press. ISBN 9780849342547. Hunt, Donald F.; McEwen, Charles N.; Harvey, T. Michael. (2002). "Positive and negative chemical ionization mass spectrometry using a Townsend discharge ion source". Analytical Chemistry. 47 (11): 1730–1734. doi:10.1021/ac60361a011. Dass, Chhabil (2007). Fundamentals of contemporary mass spectrometry ([Online-Ausg.]. ed.). Hoboken, N.J.: Wiley-Interscience. ISBN 9780470118498.
An eminent historian nominated by the Government of India who shall be Chairman of the Council Eighteen historians nominated by the Government of India; Representative of the University Grants Commission (UGC) Director General of the Archaeological Survey of India Director General of the National Archives of India Four persons to represent government who shall be nominated by the Government of India and which shall include one representative each of the Ministry of Education, the Department of Culture and the Ministry of Finance, and the Member Secretary, who is appointed by the Council of the ICHR on a deputation basis for a period of three years, with the approval of the Ministry of Human Resource Development, Government of India.
Sources: en.wikipedia.org
It is a synthetic peptide fragment derived from the C-terminal region of human growth hormone, commonly referred to as hGH fragment 176-191. It has been investigated for effects on fat metabolism, but it is not an approved medication in most jurisdictions.
No. It is a shortened peptide fragment, not the full hormone. It does not contain the entire hGH sequence and is studied for different proposed effects.
Regulatory approvals for weight loss are not established in major jurisdictions. Some human trials reported modest changes, but the evidence is limited, and it remains a research compound.
It is proposed to promote lipolysis in fat tissue, the breakdown of stored fat into fatty acids and glycerol. The detailed receptor and signaling mechanisms are not fully established.